CAPRCAPRICOR THERAPEUTICS, INC.
Pharmaceutical Preparations
- Revenue
- $0
- 100% YoY
- Operating margin
- —
- EBITDA
- −$106M
- 158% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $245K | $3M | $25M | $22M | $0 | 100% |
| Operating income | −$21M | −$30M | −$24M | −$43M | −$108M | 154% |
| Net income | −$20M | −$29M | −$22M | −$40M | −$105M | 160% |
| Operating cash flow | −$17M | $5M | −$26M | −$40M | −$70M | 75% |
| Capex | $1M | $2M | $1M | $1M | $3M | 149% |
| Stock-based comp | $3M | $4M | $7M | $10M | $17M | 76% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | $7M | 748 | — |
| FY2024 | $2M | $5M | 358 | — |
| FY2023 | $774K | $1M | 127 | — |